Ipilimumab: all 592 studies that test it

Page 4 of 6. Open to participants first (76), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate CancerTerminatedNCT06388369Phase 1/2
• Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaWithdrawnNCT06365619Phase 2
• Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma PatientsActive, not recruitingNCT06250335Phase 2
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 1
• Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic CancerCompletedNCT05721846Phase 1
• Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesCompletedNCT05704933Early Phase 1
• Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic TherapyCompletedNCT05665348Phase 2/3
• Intrathecal Double Checkpoint InhibitionActive, not recruitingNCT05598853Phase 1
• Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Active, not recruitingNCT05501054Phase 1/2
• Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantWithdrawnNCT05457959Phase 1
• A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative NeoplasmsCompletedNCT05444530Phase 1
• Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsActive, not recruitingNCT05407441Phase 1/2
• Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCActive, not recruitingNCT05401786Phase 2
• Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesTerminatedNCT05341349Phase 1
• Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid TumorsCompletedNCT05302921Phase 2
• CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaActive, not recruitingNCT05289193Phase 2
• Sargramostim With Ipilimumab Containing Therapy in Patients With Solid TumorsWithdrawnNCT05284214Phase 2
• NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasCompletedNCT05262556Phase 1
• Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial CancerCompletedNCT05219435Phase 2
• CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyActive, not recruitingNCT05215470Phase 2
• A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabTerminatedNCT05199285Phase 2
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
• Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)CompletedNCT05169957Phase 1
• EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCActive, not recruitingNCT05150236Phase 2
• Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell CancerActive, not recruitingNCT05148546Phase 2
• A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingNCT05144854Phase 3
• A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsCompletedNCT05136677Phase 2
• Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.TerminatedNCT05116917Phase 2
• A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed GlioblastomaTerminatedNCT05074992Phase 2
• Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesActive, not recruitingNCT05012254Phase 2
• Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal MelanomaCompletedNCT05004025Phase 1
• Axitinib + Ipilimumab in Advanced MelanomaActive, not recruitingNCT04996823Phase 2
• Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOmaCompletedNCT04988841Phase 2
• Combination Immunotherapy in Rare Cancers Under InvesTigationActive, not recruitingNCT04969887Phase 2
• Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic MelanomaTerminatedNCT04967196Phase 1
• Study of Nivolumab-Ipilimumab and cfDNA in Lung CancerTerminatedNCT04966676Phase 2
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 2
• Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2
• A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.CompletedNCT04855929Phase 1
• Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsSuspendedNCT04840589Phase 1
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerActive, not recruitingNCT04751370Phase 2
• Metastatic Solid Cancer Clinical TrialActive, not recruitingNCT04739618Phase 2
• Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialCompletedNCT04721301Phase 1
• Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerCompletedNCT04717154Phase 2
• A Phase 2 Trial for Patients With Metastatic Solid CancerActive, not recruitingNCT04713371Phase 2
• A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04709276Phase 2
• Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to SurgeryCompletedNCT04620200Phase 2
• Surgical Nivolumab And Ipilimumab For Recurrent GBMActive, not recruitingNCT04606316Phase 1
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• Nivolumab+Ipilimumab+RT in MSS mCRCStatus unknownNCT04575922Phase 2
• Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid TumorsStatus unknownNCT04571632Phase 2
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsActive, not recruitingNCT04562129Phase 2
• Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1
• Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1
• A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)CompletedNCT04495257Phase 1
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsWithdrawnNCT04495010Phase 2
• ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or MyxofibrosarcomaActive, not recruitingNCT04480502Phase 2
• Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorCompletedNCT04465643Phase 1
• A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced MelanomaActive, not recruitingNCT04464759Phase 1/2
• Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesCompletedNCT04463368Phase 1
• Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryTerminatedNCT04429321Phase 1
• Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingNCT04388852Phase 1
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerCompletedNCT04362839Phase 1
• Nivolumab + Ipilimumab + Radiation in MSS Pancreatic CancerActive, not recruitingNCT04361162Phase 2
• A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsCompletedNCT04338724Phase 1
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENActive, not recruitingNCT04317105Phase 1/2
• Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof MutationWithdrawnNCT04315155Phase 1
• CIML NK Cell in Head & Neck CancerCompletedNCT04290546Phase 1
• Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersTerminatedNCT04270864Phase 1
• Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerTerminatedNCT04258150Phase 2
• COL Immunotherapy Before Radiochimio + IpilimumabCompletedNCT04256213Not applicable
• A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Status unknownNCT04250246Phase 2
• Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.CompletedNCT04247165Phase 1/2
• GVAX Plus Checkpoint Blockade in NeuroblastomaTerminatedNCT04239040Phase 1
• Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1
• Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTerminatedNCT04185311Phase 1
• Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2
• A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenActive, not recruitingNCT04145115Phase 2
• Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCActive, not recruitingNCT04141644Phase 1
• Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.Status unknownNCT04134182Phase 2
• Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaCompletedNCT04133948Phase 1/2
• A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadCompletedNCT04132817Phase 1
• Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal CancerCompletedNCT04124601Phase 2
• Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerActive, not recruitingNCT04117087Phase 1
• A Phase 2 Trial for Men With Metastatic Prostatic AdenocarcinomaCompletedNCT04090775Phase 2
• Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck CancerActive, not recruitingNCT04080804Phase 2
• CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)WithdrawnNCT04060407Phase 1/2
• Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCActive, not recruitingNCT04043195Phase 1/2
• Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsCompletedNCT04042753Phase 2
• A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedNCT04039607Phase 3
• Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabActive, not recruitingNCT04013854Phase 2
• Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerActive, not recruitingNCT04013542Phase 1
• A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnNCT04007588Phase 2
• IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMActive, not recruitingNCT04003649Phase 1
• Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and ChemotherapyWithdrawnNCT03982121Phase 1
• A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTerminatedNCT03978611Phase 1
• An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersCompletedNCT03956680Phase 1
• Cryotherapy With in Situ Immunotherapy in Melanoma MetastasisCompletedNCT03949153Phase 1/2

← Ipilimumab overview